J&J, HHS sign expanded deal to find COVID-19 vaccine

Johnson & Johnson (J&J) unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services ( HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.

Americas

Genmab locked in J&J royalty payments dispute

24 September 2020 Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Americas

HHS commits to IP transparency following watchdog’s criticism

26 November 2020 The US Department of Health and Human Services will reveal more information regarding its licensing of IP to private companies for drug development, it has confirmed in a letter to a congressional watchdog.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Americas

Genmab locked in J&J royalty payments dispute

24 September 2020 Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Americas

HHS commits to IP transparency following watchdog’s criticism

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Americas

Genmab locked in J&J royalty payments dispute

24 September 2020 Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Americas

HHS commits to IP transparency following watchdog’s criticism